위 또는 위루관 시장 : 제품 유형, 용도, 최종사용자, 유통 채널별 - 예측(2026-2032년)

The Gastric or Gastrostomy Tubes Market was valued at USD 2.41 billion in 2025 and is projected to grow to USD 2.51 billion in 2026, with a CAGR of 5.45%, reaching USD 3.49 billion by 2032.

A concise orientation explaining clinical imperatives, device evolution, and stakeholder priorities reshaping gastric and gastrostomy tube utilization across care settings

Gastric and gastrostomy tubing remains a foundational component of modern enteral care, supporting diverse clinical objectives from short-term decompression to long-term nutritional therapy. Advances in device design and insertion techniques have expanded therapeutic options while elevating expectations for safety, patient comfort, and usability across inpatient and outpatient settings. Clinicians, supply chain leaders, and device manufacturers are convening around common priorities: minimizing complication rates, streamlining insertion and maintenance workflows, and delivering cost-efficient solutions that preserve quality of care.

Over the past decade, incremental innovation in materials science, retention mechanisms, and low-profile form factors has altered procurement criteria and clinical protocols. Simultaneously, regulatory scrutiny and reimbursement considerations have prompted more rigorous evidence generation and post-market surveillance. This combination of clinical demand and regulatory pressure has accelerated adoption of devices that demonstrably reduce adverse events and decrease caregiver burden. Consequently, decision-makers are evaluating devices not only on product specifications but also on training requirements, compatibility with existing inventory, and the ability of suppliers to guarantee consistent quality and timely delivery.

Key transformative shifts driven by clinical, technological, and operational forces that are redefining device selection, care pathways, and supply approaches in enteral access therapy

The landscape for gastric and gastrostomy tubes is undergoing transformative shifts driven by converging clinical, technological, and operational trends. Minimally invasive insertion techniques and expanded use of low-profile devices are redefining post-procedure management, encouraging earlier transitions from acute care to outpatient and home-based therapy. Concurrently, material innovations and improved retention mechanisms are reducing device-related complications, which in turn influences clinician preferences and institutional procurement strategies.

Operational pressures within hospitals and ambulatory centers are prompting greater emphasis on product standardization and supplier consolidation to achieve predictable inventory turnover and simplified clinician training. At the same time, the rise of telehealth-enabled home healthcare monitoring and more robust caregiver education programs is supporting safe long-term gastrostomy care outside hospital walls. Moreover, heightened regulatory attention to device labeling and adverse event reporting is encouraging manufacturers to invest in clinical evidence and quality systems, thus raising the bar for market entry and reinforcing the competitive advantage of established players with proven compliance capabilities.

Assessing the cumulative operational and strategic effects of 2025 tariff measures on supply chains, sourcing strategies, and cost dynamics within enteral access device production

The implementation of new tariff measures in 2025 has created material operational and strategic implications for stakeholders in the gastric and gastrostomy tubes space. Import-sensitive components such as specialized polymers, silicone compounds, and certain manufacturing equipment have experienced elevated landed costs due to increased duties and associated logistical premiums. Manufacturers that rely on cross-border supply chains have adjusted sourcing strategies, seeking regional suppliers or alternative input specifications to mitigate exposure to tariff volatility.

In response, device producers have pursued several adaptation pathways. Some have localized critical manufacturing steps or established regional assembly hubs to preserve competitiveness and shorten inbound lead times. Others have restructured supplier contracts to shift cost-sharing dynamics or accelerated qualification of alternative materials that meet clinical and regulatory benchmarks. For purchasers, procurement cycles now incorporate tariff impact assessments when evaluating total cost of ownership and long-term vendor relationships. Healthcare providers and group purchasing organizations are increasingly requesting transparency on tariff-related cost components and supplier resilience plans to ensure continuity of care and to avoid unforeseen budgetary pressures.

Furthermore, tariff-driven cost adjustments have incentivized efficiency gains across manufacturing and distribution, prompting investments in automation, process optimization, and inventory management technologies. These operational responses aim to offset tariff-induced input cost increases while preserving product quality and maintaining access across care settings. As a result, stakeholders who proactively addressed tariff exposure through supply diversification and process improvements are better positioned to sustain service levels and manage procurement predictably.

Integrated segmentation analysis linking product families, clinical applications, user environments, and distribution pathways to inform procurement and clinical protocol decisions

Product segmentation in this sector encompasses distinct device families that align with varied clinical scenarios and patient needs. Devices are grouped under low-profile designs, percutaneous endoscopic systems, and radiologically inserted devices. Within the low-profile category, manufacturers differentiate between balloon retention and bumper retention modalities, with balloon variants further divided into one-time and refillable options to support single-use protocols or longer-term therapy. Similarly, percutaneous endoscopic products are available with either balloon or bumper retention to accommodate clinician preference and anatomical considerations, and radiologically inserted devices mirror these retention configurations to suit image-guided placement workflows.

Applications for these devices span drainage, medication administration, and nutrition delivery, reflecting the procedural and therapeutic breadth of enteral access. Drainage use cases include gastric decompression and gastric sampling, each carrying specific design and handling requirements. Medication administration spans liquid and powdered formulations, driving requirements for lumen size, port design, and flushing protocols. Nutrition delivery differentiates between bolus feeding and continuous feeding regimens, which influence tube diameter, material resilience, and compatibility with feeding pumps.

End users range from ambulatory surgical centers and home healthcare settings to hospital environments, each imposing unique operational constraints and service expectations. Ambulatory surgical centers include day surgery centers and outpatient clinics where rapid turnover and simple device handling are prioritized. Home healthcare encompasses nursing service support and self-administration contexts, emphasizing ease of use, caregiver training, and remote support. Hospitals cover both secondary and tertiary care facilities with diverse procedural volumes and complexity profiles.

Distribution channels shape product accessibility and procurement cadence through direct tenders, distributor networks, and online platforms. Distributors include local wholesalers and specialized medical distributors that provide logistical reach and inventory services, while online channels encompass e-commerce vendors and original equipment manufacturer platforms that offer direct access and digital ordering convenience. The interplay of product features, clinical applications, user environment, and distribution pathways informs purchasing decisions, clinical guidelines, and supplier selection processes, requiring an integrated assessment when evaluating new device introductions or standardizing formularies.

Regional dynamics and differentiated adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform supply, regulation, and clinical adoption strategies

Regional trends demonstrate distinct drivers and adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions that influence device selection, supply chain strategies, and clinical practice adoption. In the Americas, adoption is often guided by a combination of clinical guideline updates, reimbursement frameworks, and a concentration of advanced acute care centers that favor devices reducing length of stay and post-procedure complications. Consequently, procurement teams in this region emphasize clinical evidence, supplier reliability, and integration with existing enteral therapy workflows.

In Europe, Middle East & Africa, regulatory harmonization efforts and cross-border procurement practices influence manufacturer strategies, with larger health systems and national procurement bodies seeking long-term supplier partnerships and consistent quality standards. Variability in healthcare infrastructure across this combined region creates demand for both high-end specialty devices suited for tertiary centers and cost-effective solutions tailored to resource-constrained settings. This dynamic stimulates product tiering and adaptable device portfolios.

Asia-Pacific exhibits rapid adoption of minimally invasive techniques and growing investment in outpatient and home-based care infrastructure. Manufacturer investments in regional production and distribution hubs are common to address logistical complexities and to shorten lead times. Across all regions, local clinical training programs, regulatory requirements, and supply chain resilience considerations shape uptake patterns, highlighting the need for manufacturers to align product design and commercial strategies with regional clinical workflows and procurement expectations.

Competitive positioning and corporate strategies emphasizing innovation, evidence partnerships, and supply resilience to secure long-term adoption in enteral access therapy

Competitive dynamics in the gastric and gastrostomy tubes landscape are characterized by product innovation, manufacturing scale, and the ability to demonstrate clinical performance through evidence generation. Leading device manufacturers maintain competitive advantage by investing in materials research to improve biocompatibility and durability, refining retention mechanisms to reduce complications, and enhancing usability features that support rapid clinician adoption and safe home use.

Partnerships between device companies and clinical centers have become an important pathway for iterative product improvement and real-world evidence collection. These collaborations support post-market surveillance and comparative performance assessments, informing labeling updates and clinician training programs. Additionally, strategic alliances with distribution partners and healthcare systems enable efficient inventory management and broaden access in outpatient and home settings.

Supply chain resilience and regulatory compliance are increasingly central to competitive positioning. Firms that have diversified component sourcing, developed regional manufacturing footprints, and implemented robust quality management systems are better equipped to manage disruptions and meet diverse regulatory requirements. Finally, companies that offer integrated service packages-including clinician training, remote monitoring tools, and comprehensive warranty and support programs-tend to achieve stronger uptake among hospitals, ambulatory centers, and home healthcare providers who value total cost of care and patient safety outcomes.

Actionable strategic priorities for manufacturers and healthcare leaders to align innovation, supply resilience, and clinician support for sustainable adoption and improved outcomes

Industry leaders should pursue a coordinated strategy that aligns product innovation with supply chain resilience and clinician-focused services to maximize adoption and patient outcomes. Prioritize investments in device features that directly reduce complication rates and simplify insertion and maintenance, thereby addressing the primary clinician and caregiver pain points. Complement product development with comprehensive training programs and digital support tools that accelerate clinician proficiency and enable safe home-based management of long-term therapies.

Strengthen supplier networks by qualifying alternative material sources and establishing regional assembly or finishing capabilities to reduce tariff exposure and shorten delivery timelines. Contractual frameworks that emphasize transparency on cost drivers and contingency planning will support stronger procurement relationships with healthcare systems. Additionally, cultivating partnerships with leading clinical centers to generate real-world evidence and post-market safety data enhances credibility and supports adoption across a broader range of care settings. Finally, design commercial models that accommodate diverse procurement channels-from direct tenders to e-commerce platforms-while offering configurable service tiers to meet the needs of tertiary hospitals, ambulatory centers, and home healthcare providers.

A rigorous mixed-methods research approach combining clinical interviews, regulatory analysis, technical review, and distribution channel mapping to produce actionable intelligence

The research methodology combines structured primary engagements, rigorous secondary review, and systematic synthesis to ensure findings reflect practical clinical realities and current regulatory landscapes. Primary inputs include interviews with clinicians across hospital, ambulatory, and home healthcare environments, discussions with procurement and supply chain professionals, and consultations with device engineers to understand design constraints and manufacturing considerations. These direct interactions provide qualitative insights into device performance, training needs, and adoption barriers.

Secondary analysis encompassed a comprehensive review of regulatory guidance documents, clinical practice guidelines, and device labeling to contextualize safety expectations and compliance trends. Patent literature and technical specifications were examined to identify material and design innovations. Distribution channel dynamics were analyzed through supplier network mapping and platform capability assessments to understand how access and procurement pathways vary by region. Throughout the process, data integrity was assured via triangulation across sources and validation checkpoints with industry experts, enabling a robust synthesis that supports actionable recommendations for stakeholders.

Synthesis of clinical, operational, and strategic conclusions emphasizing evidence-driven adoption, supply stability, and user-centered device design

Gastric and gastrostomy tubes remain essential clinical tools whose effectiveness depends on the confluence of device design, clinician competency, and resilient supply models. Emerging device innovations and procedural refinements are enabling safer transitions to outpatient and home-based care, while regulatory scrutiny and tariff dynamics are prompting more strategic supply chain configurations. Stakeholders that prioritize clinical evidence, supply diversification, and end-user support will be better positioned to navigate operational pressures and to improve patient outcomes.

Decision-makers should view device selection through a systems lens that accounts for insertion workflows, post-procedural care, caregiver capabilities, and distribution reliability. By aligning product portfolios with clinical needs and by investing in training and service infrastructure, manufacturers and providers can reduce complications, streamline care pathways, and expand access to appropriate enteral therapies. In summary, the sector's near-term trajectory favors practical innovations that deliver measurable improvements in safety, usability, and operational predictability.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastric or Gastrostomy Tubes Market, by Product Type

• 8.1. Percutaneous Endoscopic
• 8.2. Radiologically Inserted

9. Gastric or Gastrostomy Tubes Market, by Application

• 9.1. Drainage
  • 9.1.1. Gastric Decompression
  • 9.1.2. Gastric Sampling
• 9.2. Medication Administration
  • 9.2.1. Liquid Medication
  • 9.2.2. Powdered Medication
• 9.3. Nutrition
  • 9.3.1. Bolus Feeding
  • 9.3.2. Continuous Feeding

10. Gastric or Gastrostomy Tubes Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Home Healthcare
  • 10.2.1. Nursing Service
  • 10.2.2. Self Administration
• 10.3. Hospitals

11. Gastric or Gastrostomy Tubes Market, by Distribution Channel

• 11.1. Offline
• 11.2. Online

12. Gastric or Gastrostomy Tubes Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Gastric or Gastrostomy Tubes Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Gastric or Gastrostomy Tubes Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Gastric or Gastrostomy Tubes Market

16. China Gastric or Gastrostomy Tubes Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. Amsino International, Inc.
• 17.7. Applied Medical Technology, Inc.
• 17.8. Avanos Medical, Inc.
• 17.9. B. Braun Melsungen AG
• 17.10. Baxter International Inc.
• 17.11. Becton, Dickinson and Company
• 17.12. Boston Scientific Corporation
• 17.13. Cardinal Health, Inc.
• 17.14. Coloplast A/S
• 17.15. CONMED Corporation
• 17.16. ConvaTec Group PLC
• 17.17. Cook Medical Incorporated
• 17.18. Danone S.A.
• 17.19. Fresenius Kabi AG
• 17.20. Halyard Health, Inc.
• 17.21. Hollister Incorporated
• 17.22. Kimberly-Clark Corporation
• 17.23. Mead Johnson Nutrition Company
• 17.24. Medtronic plc
• 17.25. Moog Inc.
• 17.26. Nestle Health Science
• 17.27. Smiths Medical
• 17.28. Vygon S.A.